PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Anticoagulation Monitoring and Reversal Strategies for Dabigatran, Rivaroxaban, and Apixaban: A Review of Clinical Effectiveness [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2012 Apr.

CONCLUSIONS AND IMPLICATIONS FOR DECISION- OR POLICY-MAKING

No evidence was found on approaches to evaluate anticoagulation levels in patients taking dabigatran, rivaroxaban, or apixaban. No evidence identifying an antidote for dabigatran, rivaroxaban, or apixaban was found. Limited evidence was identified on rivaroxaban and dabigatran reversal strategies, in particular the use of PCC to reverse the anticoagulant effect of rivaroxaban and the use of hemodialysis to remove dabigatran from the blood. The application of these strategies in clinical practice for managing patients experiencing bleeding is uncertain. No relevant economic information was retrieved.

PREPARED BY:

  • Canadian Agency for Drugs and Technologies in Health
    Tel: 1-866-898-8439
Copyright © CADTH March 2012.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Cover of Anticoagulation Monitoring and Reversal Strategies for Dabigatran, Rivaroxaban, and Apixaban: A Review of Clinical Effectiveness
Anticoagulation Monitoring and Reversal Strategies for Dabigatran, Rivaroxaban, and Apixaban: A Review of Clinical Effectiveness [Internet].

Download

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...